Shares of Annovis Bio, Inc. (ANVS) have gained 0.1% over the past four weeks to close the last trading session at $7.29, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $33.50 indicates a potential upside of 359.5%.The average comprises four short-term price targets ranging from a low of $13 to a high of $72, with a standard deviation of $26.26. While the lowest estimate indicat ...

MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases. “This publication is a testament to ...

MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases. "This publication is a testament to m ...

公司财务业绩公布 - 公司于2023年12月31日结束的第四季度和财政年度发布了财务业绩[3] - 公司宣布了财务业绩的新闻发布会[3] 公司领导签署报告 - 公司总裁兼首席执行官Maria Maccecchini签署了报告[5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2540421 (State or other jurisdiction of incorporation or organiz ...

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson's disease (PD). Topline efficacy data is expected in June. The Phase III study was completed in 4Q 2023 with an original plan for data announcement in 1Q 2024, however the Company f ...

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as compared to 0.3 for placebo, consistent with our previous Phase II AD/PD and Discover studies Plasma Tau protein levels are reduced, consistent with our previous Phase II biomarker dataBased on the findings of this symptomatic study, Annovis plans to conduct a pivotal disease-modifying Phase III tr ...

Shares of Annovis Bio, Inc. (ANVS) have gained 0.9% over the past four weeks to close the last trading session at $11.88, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.40 indicates a potential upside of 198%.The mean estimate comprises five short-term price targets with a standard deviation of $22.13. While the lowest estimate of $13 indicates a 9.4% increase from the curr ...

Shares of Annovis Bio, Inc. (ANVS) have gained 23.8% over the past four weeks to close the last trading session at $11.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.40 indicates a potential upside of 218.9%.The average comprises five short-term price targets ranging from a low of $13 to a high of $72, with a standard deviation of $22.13. While the lowest estimate indic ...

公司概况 - 公司是一家处于临床阶段的药物平台公司，致力于治疗神经退行性疾病，如阿尔茨海默病（AD）和帕金森病（PD）[315][1] 财务状况 - 公司2023年研发支出为38790.6千美元，较2022年增加了22275.1千美元[325][1] - 公司2023年总务及行政支出为6244.4千美元，较2022年减少了2751.3千美元[326][1] - 公司2023年权证公允价值变动减少11837.2千美元，主要由于股价变动[327][1] - 公司2023年经营活动现金流为-39967.3千美元，较2022年增加[333][1] - 公司2023年融资活动现金流为17344.3千美元，较2022年增加[334][1] - 公司2023年净亏损为5,620.43万美元，较2022年增加[383][1] - 公司2023年现金及现金等价物减少至575.47万美元，较2022年大幅下降[380][1] 股权激励 - 公司2023年股票期权支出为460万美元，较2022年下降[344][1] - 公司2023年发放的股票期权分别为367,329和348,294份[424][1] - 公司2023年未行使的股票期权数量为1,954,774份，行使的数量为59,897份[424][1] 内部控制 - 公司内部控制报告显示，截至2023年12月31日，公司的内部控制有效[355][1] - 公司在2022年12月31日的年度报告中披露了关于内部控制的重大缺陷，经过改进后已得到纠正[356][1] - 公司在2023年12月31日解决了财务报告内部控制的重大缺陷[353][1] 股权发行 - 公司与BofA Securities, Inc.和ThinkEquity LLC签订了ATM股权发行销售协议，最高募集金额为5000万美元[330][1] - 公司终止了与BofA和ThinkEquity的销售协议，之前已售出704,000股普通股，募集资金760万美元[330][1] - 公司与Canaccord Genuity LLC签订了承销协议，募集净收益约683万美元[330][1]